Two years safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with HBV-induced cirrhosis

被引：0
|
作者：
Strasser, S. I.
Gane, E. J.
Weilert, F.
Sievert, W.
George, J.
Crawford, D.
Ngu, M. C.
Heathcote, E. J.
Marcellin, P.
Sorbel, J.
Rousseau, F.
机构：
[1] Royal Prince Alfred Hosp, AW Morrow GE & Liver Ctr, Sydney, NSW, Australia
[2] Middlemore Hosp, Dept Gastroenterol, Manukau City, New Zealand
[3] Waikato Hosp, Hamilton, New Zealand
[4] Monash Med Ctr, Clayton, Vic, Australia
[5] Westmead Hosp, Storr Liver Unit, Univ Sydney, Westmead, NSW, Australia
[6] Princess Alexandra Hosp, Dept Gastroenterol & Hepatol, Woolloongabba, Qld, Australia
[7] Concord Repatriat Gen Hosp, Dept Gastroenterol, Concord, NSW, Australia
[8] Univ Toronto, Dept Gastroenterol, Toronto, ON M5S 1A1, Canada
[9] Univ Paris, Clichy, France
[10] Gilead Sci Inc, Durham, NC USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2009年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A309 / A309
页数：1
相关论文
共 50 条
  • [31] CHRONIC HBV PATIENTS WHO SWITCHED TO TENOFOVIR ALAFENAMIDE (TAF) AFTER EITHER 2 OR 3 YEARS OF PRIOR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT DEMONSTRATED IMPROVEMENT IN BONE AND RENAL SAFETY
    Buti, Maria
    Izumi, Namiki
    Lim, Young-Suk
    Janssen, Harry L.
    Kao, Jia-Horng
    Streinu-Cercel, Adrian
    Nurmukhametova, Elena
    Ma, Xiaoli
    Tabak, Omer
    Jablkowski, Maciej
    Suri, Vithika
    Flaherty, John F.
    Lau, Audrey H.
    Gaggar, Anuj
    Mo, Shuyuan
    Chowdhury, Abhijit
    Fung, Scott
    Chuang, Wan-Long
    Gane, Edward
    GASTROENTEROLOGY, 2019, 156 (06) : S1195 - S1196
  • [32] Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis
    Butil, M.
    Hadziyannis, S.
    Mathurin, P.
    Urbanek, P.
    Sherman, M.
    Strasser, S.
    Wang, C.
    Petersen, J.
    Sorbel, J.
    Mondou, E.
    Anderson, J.
    Rousseau, F.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S33 - S33
  • [33] COMPARATIVE EFFICACY AND RENAL SAFETY OF ENTECAVIR, TENOFOVIR DISOPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE FOR HBV-INFECTED CANCER PATIENTS UNDERGOING CHEMOTHERAPY
    Lee, I-Cheng
    Lan, Keng-Hsin
    Su, Chien-Wei
    Chao, Yee
    Lin, Han-Chieh
    Hou, Ming-Chih
    Huang, Yi Hsiang
    HEPATOLOGY, 2021, 74 : 473A - 474A
  • [34] IMPACT OF COADMINISTRATION WITHOUT OR WITH FOOD ON THE 96-WEEK EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TAF
    Kao, Jia-Horng
    Chuang, Wan-Long
    Chen, Chi-Yi
    Ahn, Sang Hoon
    Fung, Scott K.
    Elkhashab, Magdy
    Hann, Hie-Won L.
    Ravendhran, Natarajan
    Nguyen, Tuan T.
    Tan, Susanna
    Flaherty, John F.
    Gagger, Anuj
    Gao, Bing
    Brainard, Diana M.
    Phan, Charles G.
    Lim, Young-Suk
    Ferret, Maria Asuncion Buti
    Lampertico, Pietro
    HEPATOLOGY, 2020, 72 : 484A - 484A
  • [35] EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN A SINGLE CENTER COHORT
    Colafigli, M.
    Prosperi, M.
    Fabbiani, M.
    Doino, M.
    Farina, S.
    Mondi, A.
    D'Avino, A.
    Fanti, I.
    Cauda, R.
    Di Giambenedetto, S.
    INFECTION, 2011, 39 : S75 - S75
  • [36] Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
    Hill, A.
    Hughes, S.
    Pozniak, A.
    HIV MEDICINE, 2018, 19 : S30 - S30
  • [37] Early switching of tenofovir disoproxil fumarate (TDF) in HIV-infected patients with TDF-induced nephrotoxicity: a prospective study
    Patamatamkul, Samadhi
    Songumpai, Nopporn
    Payoong, Paruspak
    Katavetin, Pisut
    Putcharoen, Opass
    HIV RESEARCH & CLINICAL PRACTICE, 2022, 23 (01) : 99 - 106
  • [38] Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
    Hill, Andrew
    Hughes, Sophie L.
    Gotham, Dzintars
    Pozniak, Anton L.
    JOURNAL OF VIRUS ERADICATION, 2018, 4 (02) : 72 - 79
  • [39] A EUROPEAN FIELD STUDY OF THE EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) AS MONOTHERAPY IN PATIENTS WITH PRIOR FAILURE TO OTHER NUCLEOSIDE/NUCLEOTIDE ANALOGUES
    van Boemmel, F.
    Zoutendijk, R.
    de Man, R.
    Bronowiki, J. -P.
    Rutter, K.
    Ferenci, P.
    Janssen, H.
    Fueloep, B.
    Brodzinski, A.
    Wiegand, J.
    Wedemeyer, H.
    Deterding, K.
    Erhardt, A.
    Hueppe, D.
    Bourliere, M.
    Sarrazin, C.
    Trojan, J.
    Buggisch, P.
    Petersen, J.
    Spengler, U.
    Kamp, A.
    Mauss, S.
    Schuchmann, M.
    van Nieuwkerk, K.
    Gerlach, T.
    Moradpour, D.
    Schweinberger, A.
    Wasmuth, H.
    Berg, T.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S216 - S216
  • [40] Efficacy of 5 Years of Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients With High Viral Load (HBV DNA ≥9 Log10 Copies/Ml)
    Gordon, Stuart C.
    Marcellin, Patrick
    Krastev, Zahary
    Horban, Andrzej
    Petersen, Joerg
    Sperl, Jan
    Phillip Dinh
    Martins, Eduardo B.
    Yee, Leland J.
    Flaherty, John F.
    Kitrinos, Kathryn M.
    Rustgi, Nika Berger Vinod K.
    Heathcote, Jenny
    GASTROENTEROLOGY, 2012, 142 (05) : S954 - S954
12345